The Milton Safenowitz Postdoctoral Fellowship Program (2023) funded by the ALS Association offers funding to postdoctoral fellows investigating amyotrophic lateral sclerosis (ALS). Priority will be given to applicants interested in specific biological targets and novel areas of research, especially:
- New target validation, including in animal models and human cell models.
- Target or pathway biology in disease-relevant models, including defining upstream/downstream modifiers and convergence of promising target pathways.
- Factors that could ultimately reduce the risk of developing ALS, including studies of genetic risk factors, epigenetics, gene-environment interactions, lifestyle, occupational or dietary factors and epidemiology.
- New biomarker identification and the development and/or validation of biomarker assays.
- Managing ALS, including the development and/or validation of novel assistive technology and measurement of patient/caregiver/family burden.
- Analysis of omics data from resources including, but not limited to, PRO-ACT, Project MinE or Answer ALS to identify disease-relevant patient subtypes, new therapeutic targets or new biomarkers.
Application is open to ALS researchers worldwide. This funding provides $150,000 USD in direct support for two years.
A letter of intent is due on March 8, 2023. Full applications are by invitation only and due on May 10, 2023.